Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356 BS during 4 week treatment duration

Phase 1

Boehringer Ingelheim

Linagliptin